Merck's cancer immunotherapy Keytruda is one of the pharma giant's rising stars, especially in the wake of evidence that the therapy had a survival benefit
over standard chemotherapy in advanced lung cancer patients.
Not exact matches
It is the first time a therapy has improved progression - free survival
over the current
standard first line treatment with platinum - based doublet
chemotherapy.»
Those who received
standard chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just
over 14 months without their disease progressing compared with about 10 months for those receiving
standard chemotherapy alone.